Dishman Netherlands is pleased to announce that the Food & Drug Administration (FDA) successfully audited its facility in Veenendaal. The audit has been concluded without483 Inspectional Observations.

The Audit was conducted over 4 days, from October 24 to 28, 2011 and covered two products; Cholesterol HP and Calcitriol.

"We are very proud of thissignificantachievement" statesHenk Pluim, CEO ofDishman Netherlands. "It isallowing us to supply commercial APIs to the US market produced in our new HiPo facility. Our Quality Assurance Management is audited by customers and local authorities quite often, but a successful FDA inspection is the icing on the cake".